Dronedarone: Current evidence for its safety and efficacy in the management of atrial fibrillation

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 27-39

  Schweizer, Patrick A ^a   Becker, Rüdiger ^a   Katus, Hugo A ^a   Thomas, Dierk ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Antiarrhythmic therapy; Atrial fibrillation; Dronedarone

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; DIGOXIN; DRONEDARONE; MACROLIDE; PHENOTHIAZINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN; DRUG DERIVATIVE;

BRADYCARDIA; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EXERCISE ELECTROCARDIOGRAPHY; EYE DISEASE; GASTROINTESTINAL SYMPTOM; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFECTION; LOADING DRUG DOSE; NAUSEA; NEUROLOGIC DISEASE; PHARMACODYNAMICS; PR INTERVAL; QT INTERVAL; QT PROLONGATION; RASH; RECURRENT DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; SINUS RHYTHM; SKIN DISEASE; SUDDEN DEATH; THYROID DISEASE; TREATMENT DURATION; COMPARATIVE STUDY; HEART FAILURE; PATHOPHYSIOLOGY; STATISTICS;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMANS;

EID: 79952937095     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S10315     Document Type: Review

References (52)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952.
2. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2002;2(3-4):118-123.
3. Wang TJ, Larson MG, Levy D, Vasan RS, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003; 107(7):2920-2925.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8): 983-988.
5. Wyse DG, Slee A, Epstein AE, et al. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm. 2004;5(11):531-537.
6. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5): 359-364.
7. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. Europace. 2006;8(9):651-745.
8. Fuster V, Ryde ́n LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. J Am Coll Cardiol. 2006;48(8):854-906.
9. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(5):2370-2375.
10. Camm JA, Reiffel JA. Defining endpoints in clinical trials on atrial fibrillation. Eur Heart J Suppl. 2008;10(Suppl H):H55-H78.
11. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009; 104(12):1534-1539.
12. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006;5(12):1034-1049.
13. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet. 2006; 367(9506):262-272.
14. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002; 415(6868):219-226.
15. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol. 2008;1(1):62-73.
16. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res. 1977;41(1):9-18.
17. Comtois P, Kneller J, Nattel S. Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry. Europace. 2005;7(suppl 2):10-20.
18. Davidenko JM, Pertsov AV, Salomonsz R, Baxter W, Jalife J. Stationary and drifting spiral waves of excitation in isolated cardiac muscle. Nature. 1992;355(6358):349-351.
19. Pertsov AM, Davidenko JM, Salomonsz R, Baxter WT, Jalife J. Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle. Circ Res. 1993;72(3):631-650.
20. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010;375(9721):1212-1223.
21. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
22. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003; 41(5):1690-1696.
23. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet. 2000;356(11):1789-1794.
24. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(11):1834-1840.
25. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(12):1825-1833.
26. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(3): 781-788.
27. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.
28. Ehrlich JR, Nattel S, Hohnloser SH. Novel anti-arrhythmic drugs for atrial fibrillation management. Curr Vasc Pharmacol. 2007;5(3): 185-195.
29. Oyetayo OO, Rogers CE, Hofmann PO. Dronedarone: a new antiarrhythmic agent. Pharmacotherapy. 2010;30(9):904-915.
30. Kathöfer S, Thomas D, Karle CA. The novel antiarrhythmic druc dronedarone: comparison with amiodarone. Cardiovasc Drug Rev. 2005;23(3):217-230.
31. Patel PD, Bhuriya R, Patel DD, Arora BL, Singh PP, Arora RR. Dronedarone for atrial fibrillation: a new therapeutic agent. Vasc Health Risk Manag. 2009;5:635-642.
32. Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol. 2002;39(5):677-684.
33. Thomas D, Kathofer S, Zhang W, et al. Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels. Br J Pharmacol. 2003; 140(5):996-1002.
34. Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol. 2003;41(2):191-202.
35. Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol. 1995;279(6): 25-32.
36. Guiraudou P, Pucheu SC, Gayraud R, et al. Involvement of nitric oxide in amiodarone- and dronedarone-induced coronary vasodilation in guinea pig heart. Eur J Pharmacol. 2004;496(8):119-127.
37. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24(8):1481-1487.
38. Pollak PT, Shafer SL. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther. 2004; 75(4):342-351.
39. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64(12): 785-791.
40. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(9): 987-999.
41. Davy JM, Herold M, Hoglund C, et al; ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156(9):527.e1-e9.
42. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358(6):2678-2687.
43. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360(2):668-678.
44. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120(9):1174-1180.
45. Torp-Pedersen C, Page RL, Connolly S, et al. The effect of dronedarone on hospitalizations in patients with atrial fibrillation. Results from the ATHENA study. Circulation. 2008;118(8):828.
46. Page RL, Connolly S, Crijns H, et al. Rhythm- and rate-controlling of dronedarone in patients with atrial fibrillation. Results from the ATHENA trial. Circulation. 2008;118(8):827.
47. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597-605.
48. Bongard V, Marc D, Philippe V, Jean-Louis M, Maryse LM. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther. 2006;13(7-8):315-319.
49. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54(12):1089-1095.
50. Hughes PJ, Freeman MK, Cohenour FV, Price EM. Dronedarone: an alternative to amiodarone? Consult Pharm. 2010;25(9):555-569.
51. Wolbrette D, Gonzalez M, Samii S, Banchs J, Penny-Peterson E, Naccarelli G. Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. Vasc Health Risk Manag. 2010;6: 517-523.
52. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc. 2009; 84(3):234-242.